Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis

Journal of Orthopaedic Research

Volumn 21, Issue 1, 2003, Pages 73-80

  Sabokbar, A ^a   Kudo, O ^a   Athanasou, N A ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; TISSUE;

BONE RESORPTION;

BONE;

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CD14 ANTIGEN; COLONY STIMULATING FACTOR 1; CYTOKINE; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN P55; PROTEIN P75; RECEPTOR SUBUNIT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; VITRONECTIN RECEPTOR;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BONE MARROW CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HIP ARTHROPLASTY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MACROPHAGE; MALE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTHESIS FAILURE; PROSTHESIS LOOSENING; STATISTICAL ANALYSIS;

ACETABULUM; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD14; ANTINEOPLASTIC AGENTS; BONE RESORPTION; CELLS, CULTURED; FEMALE; FIBROBLASTS; GLYCOPROTEINS; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; PROSTHESIS FAILURE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037260653     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-0266(02)00106-7     Document Type: Article

References (59)

1. Algan SM, Purdon M, Horowitz SM. Role of tumor necrosis factor alpha in particulate-induced bone resorption. J Orthop Res 1996;14(1):30-5.
2. Alldred A. Etanercept in rheumatoid arthritis. Expert Opin Pharmacother 2001;2:1137-48.
3. Amstutz HC, Campbell P, Kossovsky N, Clarke IC. Mechanisms and clinical significance of wear debris-induced osteolysis. Clin Orthop 1992:276:7-18.
4. Athanasou NA, Quinn J. Immunophenotypic differences osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol 1990;43(12):997-1003.
5. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000;275:4858-64.
6. Brändström H, Jonsson KB, Vidal O, Ljunghall S, Ohlsson C, Ljunggren Ö. Tumor necrosis factor-α and -β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 1998;248:454-7.
7. Bullough PG, DiCarlo EF, Hansraj KK, Neves MC. Pathologic studies of total joint replacement. Orthop Clin North Am 1988;19:611-25.
8. Chiba J, Rubash HE, Kim KJ, Iwaki Y. The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis. Clin Orthop 1994;300:304-12.
9. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM. Efficacy of etanercept for wear debris-induced osteolysis. J Bone Miner Res 2001;16:338-47.
10. Clohisy JC, Abu Amer Y. Tumour necrosis factor, via its type 1 receptor, mediates PMMA induction of p65 and p50 NF-κB transactivation in osteoclast precursor cells. Trans Orthop Res Soc 2001;26:497.
11. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-7.
12. Fujikawa Y, Quinh JMW, Sabokbar AS, McGee JOD, Athanasou NA. The human mononuclear osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996;137:4058-60.
13. Fujikawa Y, Sabokbar A, Neale SD, Athanasou NA. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis 1996;55:816-22.
14. Goodman SB, Chris RC, Chiou SS, Schurman DJ, Woolson ST, Masada MP. A clinical pathological-biochemical study of the membrane surrounding loosened and non loosened total hip arthroplasties. Clin Orthop 1989;244:182-7.
15. Harris WH. Osteolysis and particle disease in hip replacements (a review). Acta Orthop Scand 1994;65:113-23.
16. Haynes DR, Boyle SJ, Rogers SD, Howie DW, Vernon-Roberts B. Variations in cytokines induced by particles from different prosthetic materials. Clin Orthop 1998;352:223-30.
17. Haynes DR, Crotti TN, Potter AE, Loric M, Atkins GJ, Howie DW, et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg 2001;83B:902-11.
18. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999:25:255-9.
19. Horowitz SM, Luchetti WT, Gonzales JB, Ritchie CK. The effects of cobalt chromium upon macrophages. J Biomed Mater Res 1998;41(3):468-73.
20. Horowitz SM, Purdon MA. Mediator interactions in macrophage/particulate bone resorption. J Biomed Mater Res 1995;29(4):477-84.
21. Horton MA, Lewis D, McNulty K, Pringle JAS, Chambers TJ. Monoclonal antibodies to osteoclastomas (giant cell bone tumours): definition of osteoclast specific cellular antigens. Cancer Res 1985;45:5663-9.
22. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997;3(11):1285-9.
23. Itonaga I, Sabokbar A, Murray DW, Athanasou NA. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. Ann Rheum Dis 2000;59:26-31.
24. Jiranek WA, Machado M, Jasty M, Jervevar D, Wolfe HJ, Goldring SR, et al. Production of cytokines around loosened cemented acetabular components. J Bone Joint Surg 1993;75A: 863-79.
25. Kim KJ, Rubash HE, Wilson SC, D'Antonio JA, McClain EJ. A histologic and biochemical comparison of the interface tissues in cementless and cemented hip prostheses. Clin Orthop 1993; 287:142-52.
26. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-86.
27. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes. Arthritis Rheum 2001;44:1003-12.
28. Kudo O, Fujikawa Y, Itonaga I, Sabokbar A, Torisu T, Athanasou NA. Pro-inflammatory cytokine (TNFα/IL-1α-induction of human osteoclast formation. J Pathol, in press.
29. Kudo O, Sabokbar A, Pocock A. Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin 11 support human osteoclast formation by a RANKL-independent mechanism. Bone, in press.
30. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93: 165-76.
31. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross PF, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
32. Lee SE, Chung WJ, Kwak HB, Chung CH, Kwack K, Lee ZH, et al. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem, in press.
33. Lerner UH, Ohlin A. Tumor necrosis factors alpha and beta can stimulate bone resorption in cultured mouse calvariae by a prostaglandin-independent mechanism. J Bone Miner Res 1993; 8(2):147-55.
34. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97:1566-71.
35. Massey HM, Flanagan AM. Human osteoclasts derive from CD14-positive monocytes. Br J Haematol 1999;106:167-70.
36. Malcolm AJ. The pathology of long standing cemented total hip replacement in Charnley's cases. J Bone Joint Surg 1988;70B:153-6.
37. Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross PF, Teitelbaum SL. TNF-alpha mediates orthopaedic implant osteolysis. Am J Pathol 1999;154:203-10.
38. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a market of osteoclast function. Calcif Tissue Int 1982;34:285-90.
39. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395-400.
40. Nakashima Y, Sun DH, Trindade MC, Maloney WJ, Goodman SB, Schurman DJ, et al. Signaling pathways for tumor necrosis factor-alpha and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. J Bone Joint Surg 1999;81A(5):603-15.
41. Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ. Fibroblastic stromal cells express receptor activator of NF-κB ligand and support osteoclast differentiation. J Bone Miner Res 2000;15:1459-66.
42. Quinn JMW, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424-7.
43. Quinn JMW, Sabokbar A, Athanasou NA. Cells of the mononuclear phagocyte series differentiate into osteoclastic lacunar bone resorbing cells. J Pathol 1996;179:106-11.
44. Revell PA. Tissue reactions to joint prostheses and the products of wear and corrosion. In: Berry C, editor. Current Trends in Pathology. Berlin: Springer-Verlag; 1982. p. 73-101.
45. Rogers SD, Howie DW, Graves SE, Pearcy MJ, Haynes DR. In vitro human monocyte response to wear particles of titanium alloy containing vanadium or niobium. J Bone Joint Surg 1997; 79B(2):311-5.
46. Sabokbar A, Fujikawa Y, Neale S, Murray DW, Athanasou NA. Human arthroplasty macrophages differentiate into osteoclastic bone resorbing cells. Ann Rheum Dis 1997;56:414-20.
47. Santavirta S, Konttinen TY, Bergroth V, Eskola A, Tallroth K, Lindholm TS. Aggressive Granulomatous lesions associated with hip arthroplasty: Immunopathological studies. J Bone Joint Surg 1990;72A:252-8.
48. Schwarz EM, Childs L, Paschalis E, Xing L, Boskey A, Boyce B, et al. Safety and efficacy of RANK:Fc treatment for the prevention and amelioration of established osteolysis. Trans Orthop Res Soc 2001;26:0137.
49. Schwarz EM, Lu AP, Goater JJ, Benz EB, Kollias G, Rosier RN, et al. Tumor necrosis factor-alpha/nuclear transcription factor-kappaB signaling in periprosthetic, osteolysis. J Orthop Res 2000;18(3):472-80.
50. Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, et al. Characterization of osteoclast precursors in human blood. Br J Haematol 2000;111:501-12.
51. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1998;89:309-19.
52. Stea S, Visentin M, Granchi D, Ciapetti G, Donati ME, Sudanese A, et al. Cytokines and osteolysis around total hip prostheses. Cytokine 2000;12(10):1575-9.
53. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-57.
54. Thomson BM, Mundy GR, Chambers TJ. Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 1987;138(3):775-9.
55. Van Furth R. Origin and turnover of monocytes and macrophages. Current Topics Pathol 1989;79:125-50.
56. Vidal ONA, Sjögren K, Eriksson BI, Ljurggren Ö, Ohlsson C. Osteoprotegerin mRNA is increased by interleukin-1α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun 1998;248:696-700.
57. Williams RO, Feldmann M, Maini RN. Cartilage destruction and bone erosions in arthritis the role of TNFα. Ann Rheum Dis 2000;59(Suppl I):i75-80.
58. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S-I, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and identical to TRANCE-RANKL. Proc Natl Acad Sci USA 1998; 95:3597-602.
59. Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 2001;83(1):70-83.